Form 8-K - Current report:
SEC Accession No. 0001013762-25-002271
Filing Date
2025-03-25
Accepted
2025-03-25 17:25:07
Documents
14
Period of Report
2025-03-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0235633-8k_hoth.htm   iXBRL 8-K 44241
2 AGREEMENT BY AND BETWEEN THE COMPANY AND ONTARGETX R&D INC. DATED MARCH 24, 2025 ea023563301ex10-1_hoth.htm EX-10.1 53363
  Complete submission text file 0001013762-25-002271.txt   288954

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE hoth-20250321.xsd EX-101.SCH 3038
4 XBRL LABEL FILE hoth-20250321_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE hoth-20250321_pre.xml EX-101.PRE 22374
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0235633-8k_hoth_htm.xml XML 3919
Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036
Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 25769411
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)